STENOCARE sign supply agreement with Emerald Health Therapeutics Inc

Download PDF

STENOCARE A/S (“STENOCARE”) hereby announce that the company has signed a new agreement to source medical cannabis for Denmark and the company’s international markets with the Canadian company Emerald Health Therapeutics Inc (“Emerald”) (TSXV: EMH; OTCQX: EMHTF). STENOCARE and Emerald will immediately commence the work with the Danish Medicines Agency (“DMA”) to have the products approved for the Danish Medical Cannabis Pilot Programme.

STENOCARE has carefully evaluated potential new suppliers of medical cannabis in order to supply products suitable for patients according to the strict requirements of the DMA. Emerald is a licensed Canadian producer of medical cannabis, which STENOCARE estimate is a partner with strong capabilities across cultivation, processing, formulation and testing, which enables a partnership fully in line with STENOCARE’s vision of supplying medical cannabis that helps patients getting a better quality of life. Emerald has a medical cannabis portfolio containing both dried and oil products. Since early September 2019, STENOCARE and Emerald have worked closely together to pre-qualify the products and production methods. After signing of the agreement, STENOCARE and Emerald will immediately commence the work with the DMA to have the products ready and approved for the Danish Medical Cannabis Pilot Programme. The companies are aiming for product approval for CBD oil, THC oil and CBD+THC oil. The partnership is also intended to extend to STENOCARE’s Irish subsidiary and to additional markets which are being evaluated.

STENOCARE’s objective is to partner with more than one supplier to secure the future product supply situation and thereby offer patients and physicians more choice for their treatment. This will also enable STENOCARE a flexibility and ensure that the company is well adapted on the medical cannabis market. STENOCARE is, and has always been, fully devoted to bringing the best quality source of product to patients on the Danish market approved for the Danish Medical Cannabis Pilot Programme.

STENOCARE’s CEO Thomas Skovlund Schnegelsberg comments: I am very pleased and excited about the new agreement with Emerald Health Therapeutics. Emerald Health Therapeutics is a strong partner which we estimate will be able to supply STENOCARE with products suitable for the strict requirements on the Danish Medical Cannabis Programme. This partnership has been carefully evaluated and we look forward to the upcoming months of work together with Emerald Health Therapeutics”

Emerald Health Therapeutics CEO Riaz Bandali comments: “We respect STENOCARE’s professionalism and their accomplishment in establishing leading distribution channels for medical cannabis in Denmark. We also appreciate their trust in Emerald’s capability’s and standards as they transition to new preferred supplier relationships. As Emerald ramps up production at its two recently fully-licensed production facilities, we look forward to fulfilling our commitment to STENOCARE and helping them to serve Danish patients.”

About Emerald Health Therapeutics Inc

Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis products focused on differentiated, value-added product development for medical cannabis supported by novel intellectual property, large-scale cultivation, extraction, and softgel encapsulation. Emerald Health Therapeutics subsidiary Verdélite is a high-quality indoor growing and processing facility in Québec focused on premium, craft cannabis strains. The executive team is highly experienced in life sciences, product development, large-scale agricultural businesses, and marketing.